{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:35:53Z","timestamp":1792791353013,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Waldenstr\u00f6m macroglobulinemia (WM) is a rare B-cell lymphoplasmacytic lymphoma associated with clonal IgM gammopathy, comprising 1%\u20132% of hematological malignancies. The clinical presentation exhibits diverse cutaneous manifestations, including paraproteinemia-related effects, autoimmune phenomena, and neoplastic cell infiltration. Next-generation Bruton tyrosine kinase inhibitors, such as zanubrutinib and acalabrutinib, have revolutionized WM treatment by enhancing selectivity but are associated with various dermatologic lesions. We report a case of a 74-year-old man with simultaneous presentation of cutaneous WM and an acalabrutinib-induced eruption. The drug reaction presented as blanching macules and papules, histologically showing superficial perivascular dermatitis and lymphocytic panniculitis with predominantly T cells. The cutaneous WM showed diffuse, dense dermal lymphocytic infiltrates, which were predominantly B cells. Recognizing these distinct histopathological patterns is crucial for accurate diagnosis and timely intervention. The evolving landscape of Bruton tyrosine kinase inhibitors necessitates vigilant clinical awareness of the delicate balance between harnessing therapeutic benefits and managing associated cutaneous complexities in patients with WM. In addition, these patients are susceptible to opportunistic infections. Awareness of the various cutaneous reactions and vigilant monitoring are required.<\/jats:p>","DOI":"10.1097\/dad.0000000000003077","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T19:00:11Z","timestamp":1753383611000},"page":"786-789","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous Presentation of Cutaneous Waldenstr\u00f6m Macroglobulinemia and Acalabrutinib-Related Toxicity"],"prefix":"10.1097","volume":"47","author":[{"given":"Tania","family":"Platero-Portillo","sequence":"first","affiliation":[{"name":"Department of Pathology and Immunology Baylor College of Medicine, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Mercado-Evans","sequence":"additional","affiliation":[{"name":"Medical Scientist Training Program, Baylor College of Medicine, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Ramani","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology Baylor College of Medicine, Houston, TX;"},{"name":"Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvaneswari","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology Baylor College of Medicine, Houston, TX;"},{"name":"Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"R1-20250919","first-page":"100527","article-title":"Current approach to Waldenstr\u00f6m macroglobulinemia","volume":"31","author":"Ravi","year":"2022","journal-title":"Cancer Treat Res Commun."},{"key":"R2-20250919","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clml.2017.02.028","article-title":"Waldenstr\u00f6m macroglobulinemia: review of pathogenesis and management","volume":"17","author":"Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"R3-20250919","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"R4-20250919","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.26788","article-title":"Bruton tyrosine kinase inhibitors in the management of Waldenstr\u00f6m macroglobulinemia","volume":"98","author":"Castillo","year":"2023","journal-title":"Am J Hematol."},{"key":"R5-20250919","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstr\u00f6m's macroglobulinemia with BTK inhibitors","volume":"37","author":"Buske","year":"2023","journal-title":"Leukemia"},{"key":"R6-20250919","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol."},{"key":"R7-20250919","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"R8-20250919","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol."},{"key":"R9-20250919","doi-asserted-by":"crossref","first-page":"adv00225","DOI":"10.2340\/00015555-3535","article-title":"Cutaneous involvement in Waldenstr\u00f6m's macroglobulinaemia","volume":"100","author":"Stien","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"R10-20250919","first-page":"75","article-title":"Cutaneous infiltration due to Waldenstrom macroglobulinemia","volume":"109","author":"Oscoz-Jaime","year":"2018","journal-title":"Actas Dermo-Sifiliogr (Engl Ed)"},{"key":"R11-20250919","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/cup.12944","article-title":"MYD88 L265P mutation in cutaneous involvement by Waldenstr\u00f6m macroglobulinemia","volume":"44","author":"Alegr\u00eda-Landa","year":"2017","journal-title":"J Cutan Pathol."},{"key":"R12-20250919","first-page":"1000","article-title":"Cutaneous macroglobulinosis deposits in a patient with IgM paraproteinemia\/incipient Waldenstr\u00f6m macroglobulinemia","volume":"8","author":"L\u00fcftl","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"R13-20250919","first-page":"5181","article-title":"A case of primary spindle cell variant of embryonal rhabdomyosarcoma of the prostate","volume":"7","author":"Asahina","year":"2014","journal-title":"Int J Clin Exp Pathol."},{"key":"R14-20250919","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R15-20250919","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"R16-20250919","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med."},{"key":"R17-20250919","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cup.14145","article-title":"Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy","volume":"49","author":"Seervai","year":"2022","journal-title":"J Cutan Pathol."},{"key":"R18-20250919","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.humpath.2023.04.014","article-title":"Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings","volume":"140","author":"Haynes","year":"2023","journal-title":"Hum Pathol."},{"key":"R19-20250919","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cup.14160","article-title":"Ibrutinib skin toxicities: report of two cases","volume":"49","author":"Bloomquist","year":"2022","journal-title":"J Cutan Pathol."},{"key":"R20-20250919","first-page":"20499361241241199","article-title":"Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature","volume":"11","author":"Nguyen","year":"2024","journal-title":"Ther Adv Infect Dis."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:00:32Z","timestamp":1758294032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003077","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}